REXULTI is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer’s diseasePRINCETON, N.J. & DEERFIELD, Ill. (BUSINESS WIRE) Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Lundbeck LLC (Lundbeck) announce the U.S. Food and Drug Administration (FDA) h.
REXULTI is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer’s diseasePRINCETON, N.J .